Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference
01 août 2023 08h00 HE | Vor Biopharma
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will host in-person 1x1 investor meetings at the 2023 Wedbush PacGrow...
AI in Context: How Quantexa Augments and Automates Decision Intelligence with AI
Quantexa Bringing Total Global Investment in Artificial Intelligence Research and Development to Over $250M by 2027
09 juil. 2023 19h01 HE | Quantexa
Quantexa CEO outlines vision for investment in support of UK Government’s plan to make UK an AI Hub, which includes: Over $155M in new global investments aimed at accelerating enterprise...
logo-header-min.png
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
26 juin 2023 07h00 HE | Marker Therapeutics
HOUSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR) (Marker or the Company), a clinical-stage immuno-oncology company focusing on developing next-generation T...
Aptose Biosciences Inc. logo
Aptose Presents Highlights from Clinical Update
10 juin 2023 12h00 HE | Aptose Biosciences, Inc.
Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat...
Vor-Wordmark-RGB-FullColor-070920.png
Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform
09 juin 2023 07h30 HE | Vor Biopharma
Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism.Strong investigator enthusiasm and continued robust enrollment; additional data...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in the Goldman Sachs Healthcare Conference
05 juin 2023 08h00 HE | Vor Biopharma
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will present and host in-person 1x1 investor meetings at the Goldman...
Melissa-new-logo-no-tag-hi-res[2].jpg
Melissa Points to Real-Time Data Quality as Key to Compliance Initiatives in Online Gambling
31 mai 2023 08h00 HE | Melissa
RANCHO SANTA MARGARITA, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Melissa, a leading provider of global data quality, identity verification, and address management solutions, today cited clean data...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
11 mai 2023 16h05 HE | Vor Biopharma
VBP101 clinical data update planned at European Hematology Association (EHA) 2023VCAR33ALLO IND submission on-track for 1H 2023 CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:...
Kura Oncology Logo
Kura Oncology Reports First Quarter 2023 Financial Results
10 mai 2023 16h03 HE | Kura Oncology, Inc.
– Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA – – Site activation and enrollment in Phase 2 registration-directed trial of ziftomenib in NPM1-mutant AML...
Quantexa-logo-positive-RGB.png
Quantexa Provides ING with Solution to Strengthen and Automate Global Risk Coverage
10 mai 2023 08h00 HE | Quantexa
LONDON, May 10, 2023 (GLOBE NEWSWIRE) -- Today Quantexa, a global leader in Decision Intelligence (DI) solutions for the public and private sectors, announced that ING is deploying Quantexa’s...